Literature DB >> 31045417

Construct validity of PROMIS® Cognitive Function in cancer patients and noncancer controls.

Thomas R Valentine1, David M Weiss1, Jeffrey A Jones2, Barbara L Andersen1.   

Abstract

OBJECTIVE: The Patient-Reported Outcomes Measurement Information System Cognitive Function-Concerns® (PROMIS®-CF-Concerns) assesses self-reported cognitive complaints. Construct validity data for the CF-Concerns are few. To add to the literature, an analysis of criterion validity for cognitive complaints (European Organisation for Research and Treatment of Cancer-Cognitive Functioning subscale [EORTC-CF]) and cognitive performance (neuropsychological tests of memory [NIH Toolbox Auditory Verbal Learning Test] and verbal fluency [Controlled Oral Word Association Test]) and discriminant validity (self-reports of negative emotions of anxiety, depression, negative mood) are provided. A two-group comparison design was used.
METHOD: Forty-four patients with chronic lymphocytic leukemia (CLL) and 44 age- and gender-matched noncancer controls completed self-report measures and neuropsychological tests. Spearman's rank correlations (rs) and independent-samples t tests were used.
RESULTS: Regarding criterion validity, PROMIS®-CF-Concerns significantly correlated with the EORTC-CF (rs = 0.77, p < .001), although not with tests of memory (-0.19) or verbal fluency (0.16). As expected, patients with CLL performed lower than did controls on neuropsychological tests (ps < .05) yet did not differ from controls on PROMIS®-CF-Concerns. PROMIS®-CF-Concerns was reliably and significantly correlated with negative emotions, with rs ranges across measures of -0.42 to -0.69 for the CLL group and -0.53 to -0.78 for controls.
CONCLUSIONS: PROMIS®-CF-Concerns exhibited high internal consistency. Criterion validity was evidenced for cognitive complaints though not for cognitive performance as assessed here. In summary, the analysis supports the criterion validity of PROMIS®-CF-Concerns for cognitive complaints. It also covaries with self-reports of co-occurring anxiety, depression, and negative mood. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Entities:  

Mesh:

Year:  2019        PMID: 31045417     DOI: 10.1037/hea0000693

Source DB:  PubMed          Journal:  Health Psychol        ISSN: 0278-6133            Impact factor:   4.267


  8 in total

1.  Longitudinal changes in patient-reported cognitive complaints among older adults with gastrointestinal malignancies - results from the Cancer and Aging Resilience Evaluation (CARE) Registry.

Authors:  Mackenzie E Fowler; Donna Murdaugh; Christian Harmon; Mustafa Al-Obaidi; Noha Sharafeldin; Smita Bhatia; Smith Giri; Grant R Williams
Journal:  J Cancer Surviv       Date:  2022-09-17       Impact factor: 4.062

2.  Cognitive impairment is associated with greater preoperative symptoms, worse health-related quality of life, and reduced likelihood of recovery after cervical and lumbar spine surgery.

Authors:  Rachel S Bronheim; Emma Cotter; Richard L Skolasky
Journal:  N Am Spine Soc J       Date:  2022-05-22

3.  Patient-reported cognitive complaints in older adults with gastrointestinal malignancies at diagnosis- Results from the Cancer & Aging Resilience Evaluation (CARE) study.

Authors:  Nabiel Mir; Paul MacLennan; Mustafa Al-Obaidi; Donna Murdaugh; Kelly M Kenzik; Andrew McDonald; Noha Sharafeldin; Crystal Young-Smith; Ravi Paluri; Olumide Gbolahan; Lakshmin Nandagopal; Smita Bhatia; Grant R Williams
Journal:  J Geriatr Oncol       Date:  2020-03-13       Impact factor: 3.599

4.  Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Kerry A Rogers; Ying Huang; Amy S Ruppert; Lynne V Abruzzo; Barbara L Andersen; Farrukh T Awan; Seema A Bhat; Allison Dean; Margaret Lucas; Christin Banks; Cara Grantier; Nyla A Heerema; Gerard Lozanski; Kami J Maddocks; Thomas R Valentine; David M Weiss; Jeffrey A Jones; Jennifer A Woyach; John C Byrd
Journal:  J Clin Oncol       Date:  2020-08-14       Impact factor: 44.544

5.  Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations from the Cancer Neuroscience Initiative Working Group.

Authors:  Ashley M Henneghan; Kathleen Van Dyk; Tara Kaufmann; Rebecca Harrison; Christopher Gibbons; Cobi Heijnen; Shelli R Kesler
Journal:  J Natl Cancer Inst       Date:  2021-02-26       Impact factor: 13.506

6.  Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study.

Authors:  Tingting Cai; Tingting Zhou; Changrong Yuan; Chunfang Yu; Feixia Ni; Zhiren Sheng
Journal:  Front Public Health       Date:  2022-08-03

7.  Cognitive dysfunction prevalence and associated factors in older breast cancer survivors.

Authors:  Adele Crouch; Victoria L Champion; Frederick W Unverzagt; Susan J Pressler; Lesa Huber; Lyndsi R Moser; David Cella; Diane Von Ah
Journal:  J Geriatr Oncol       Date:  2021-07-08       Impact factor: 3.599

8.  Exploring stress, cognitive, and affective mechanisms of the relationship between interpersonal trauma and opioid misuse.

Authors:  Jessica Roberts Williams; Veronica Cole; Susan Girdler; Martha Grace Cromeens
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.